[Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-A Case Report]. 2019

Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
Dept. of Surgery, Tohoku University Graduate School of Medicine.

We report a case of locally advanced unresectable(UR-LA)pancreatic cancer in a patient who underwent conversion surgery after FOLFIRINOX and proton beam therapy(PBT)combined with S-1. A 68-year-old woman was referred to our hospital for a pancreatic tumor. The abdominal CT scan revealed a 40mm pancreatic body tumor with an abutment(>180°) of the celiac artery and the superior mesenteric artery. Moreover, the tumor was classified as UR-LA with a contact to the abdominal aorta. The tumor was histologically diagnosed as adenocarcinoma via an endoscopic ultrasound-guided fine-nee- dle aspiration. After 2 courses of FOLFIRINOX, PBT(50 GyE/25 Fr)combined with S-1 were administered. The tumor shrunk to 30mm at the CT scan. After 5 courses of FOLFIRINOX, the tumor reduced to 20 mm. No distant metastasis or malignant cells in abdominal washing cytology was detected using staging laparoscopy. Then, distal pancreatectomy with celiac axis resection(DP-CAR)was performed. According to the General Rules for the Study of Pancreatic Cancer(7th edition)from Japan Pancreas Society, the histological findings were suggestive of ypT3, ypN0, R0, and Grade 3 histological effect. The patient had a Grade A delayed gastric emptying post-operation. He was discharged 35 days after the surgery and has been alive without recurrence on imaging for 11 months post-operation.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010180 Pancreatectomy Surgical removal of the pancreas. (Dorland, 28th ed) Pancreatectomies
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D061766 Proton Therapy The use of an external beam of PROTONS as radiotherapy. Proton Beam Radiation Therapy,Proton Beam Therapy,Proton Beam Therapies,Proton Therapies,Therapies, Proton,Therapies, Proton Beam,Therapy, Proton,Therapy, Proton Beam
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
December 2019, Gan to kagaku ryoho. Cancer & chemotherapy,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
November 2015, Gan to kagaku ryoho. Cancer & chemotherapy,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
August 2023, Gan to kagaku ryoho. Cancer & chemotherapy,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
January 2023, Journal of hepato-biliary-pancreatic sciences,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
February 2022, The Journal of surgical research,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
October 2018, Molecular and clinical oncology,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
December 2023, Gan to kagaku ryoho. Cancer & chemotherapy,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
September 2018, Surgical case reports,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
August 2021, Annals of hepato-biliary-pancreatic surgery,
Yuichiro Umino, and Masamichi Mizuma, and Masahiro Iseki, and Tatsuo Hata, and Tatsuyuki Takadate, and Kei Kawaguchi, and Takeshi Aoki, and Fuyuhiko Motoi, and Takeshi Naito, and Takashi Kamei, and Atsushi Masamune, and Chikashi Ishioka, and Takashi Ono, and Masao Murakami, and Michiaki Unno
September 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!